%0 Journal Article
%T The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer
%A Fei-Ran Gong
%A Jing Wu
%A Kai Chen
%A Liu-Mei Shou
%A Lu Liu
%A Meng-Dan Xu
%A Meng-Yao Wu
%A Min Jiang
%A Min Tao
%A Qiaoming Zhi
%A Wei Li
%A Wen-Jie Wang
%A Yan Zhang
%J Archive of "Oncogenesis".
%D 2018
%R 10.1038/s41389-018-0102-2
%X PANC-1 cells were used in both subcutaneous and orthotopic pancreatic xenograft models. a, b Body weight (a) and tumor volume (b) evaluations of the cantharidin (CAN) group vs. the control group in subcutaneous xenografts. c, d Representative in vivo bioluminescent images (c) and bioluminescence analysis (d) of pancreatic cancer subcutaneous xenografts. e, f Photographs of subcutaneous xenograft (e) and tumor weight (f) in the CAN vs. the control group. g Body weight of the CAN vs. the control group in orthotopic xenografts. h, i Representative bioluminescent images (h) and bioluminescence analysis (i) of pancreatic cancer orthotopic xenografts. j, k Photographs of orthotopic xenograft (j) and tumor weight (k) in the CAN vs. the control group. l, m The bioluminescent images showing the process of bioluminescence peak emergence and decay in the CAN vs. the control group in subcutaneous (l) and orthotopic xenografts (m). *P£¿<£¿0.05 and **P£¿<£¿0.01, significant differences vs. the control grou
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255842/